nodes	percent_of_prediction	percent_of_DWPC	metapath
Pyrimethamine—DHFR—Methotrexate—urinary bladder cancer	0.47	0.667	CbGbCtD
Pyrimethamine—CYP2C8—Fluorouracil—urinary bladder cancer	0.0673	0.0956	CbGbCtD
Pyrimethamine—CYP2C8—Etoposide—urinary bladder cancer	0.0562	0.0798	CbGbCtD
Pyrimethamine—CYP2C9—Fluorouracil—urinary bladder cancer	0.0469	0.0667	CbGbCtD
Pyrimethamine—CYP2C9—Cisplatin—urinary bladder cancer	0.0399	0.0566	CbGbCtD
Pyrimethamine—CYP2D6—Doxorubicin—urinary bladder cancer	0.0244	0.0347	CbGbCtD
Pyrimethamine—CYP2C9—urine—urinary bladder cancer	0.00493	0.15	CbGeAlD
Pyrimethamine—DHFR—prostate gland—urinary bladder cancer	0.00401	0.122	CbGeAlD
Pyrimethamine—CYP2D6—urine—urinary bladder cancer	0.0037	0.112	CbGeAlD
Pyrimethamine—Anaemia megaloblastic—Methotrexate—urinary bladder cancer	0.0037	0.0622	CcSEcCtD
Pyrimethamine—DHFR—seminal vesicle—urinary bladder cancer	0.0034	0.103	CbGeAlD
Pyrimethamine—Haematuria—Valrubicin—urinary bladder cancer	0.00312	0.0524	CcSEcCtD
Pyrimethamine—DHFR—renal system—urinary bladder cancer	0.00274	0.0831	CbGeAlD
Pyrimethamine—DHFR—urethra—urinary bladder cancer	0.00269	0.0816	CbGeAlD
Pyrimethamine—Pancytopenia—Mitomycin—urinary bladder cancer	0.0024	0.0404	CcSEcCtD
Pyrimethamine—DHFR—female reproductive system—urinary bladder cancer	0.00219	0.0665	CbGeAlD
Pyrimethamine—DHFR—vagina—urinary bladder cancer	0.00198	0.0602	CbGeAlD
Pyrimethamine—Leukopenia—Mitomycin—urinary bladder cancer	0.00158	0.0265	CcSEcCtD
Pyrimethamine—Thrombocytopenia—Mitomycin—urinary bladder cancer	0.00141	0.0237	CcSEcCtD
Pyrimethamine—Anorexia—Mitomycin—urinary bladder cancer	0.00137	0.023	CcSEcCtD
Pyrimethamine—CYP2C8—renal system—urinary bladder cancer	0.00136	0.0412	CbGeAlD
Pyrimethamine—Vomiting—Valrubicin—urinary bladder cancer	0.00133	0.0223	CcSEcCtD
Pyrimethamine—DHFR—lymph node—urinary bladder cancer	0.00128	0.0389	CbGeAlD
Pyrimethamine—Decreased appetite—Mitomycin—urinary bladder cancer	0.00125	0.021	CcSEcCtD
Pyrimethamine—Pancytopenia—Thiotepa—urinary bladder cancer	0.00121	0.0203	CcSEcCtD
Pyrimethamine—Toxic epidermal necrolysis—Gemcitabine—urinary bladder cancer	0.00111	0.0187	CcSEcCtD
Pyrimethamine—CYP2C8—female reproductive system—urinary bladder cancer	0.00109	0.033	CbGeAlD
Pyrimethamine—Haematuria—Thiotepa—urinary bladder cancer	0.00108	0.0182	CcSEcCtD
Pyrimethamine—Pancytopenia—Gemcitabine—urinary bladder cancer	0.00102	0.0171	CcSEcCtD
Pyrimethamine—Pancytopenia—Fluorouracil—urinary bladder cancer	0.000998	0.0168	CcSEcCtD
Pyrimethamine—CYP2C8—vagina—urinary bladder cancer	0.000984	0.0299	CbGeAlD
Pyrimethamine—CYP2C9—female reproductive system—urinary bladder cancer	0.000966	0.0293	CbGeAlD
Pyrimethamine—Toxic epidermal necrolysis—Etoposide—urinary bladder cancer	0.000951	0.016	CcSEcCtD
Pyrimethamine—Pancytopenia—Cisplatin—urinary bladder cancer	0.000946	0.0159	CcSEcCtD
Pyrimethamine—Stevens-Johnson syndrome—Gemcitabine—urinary bladder cancer	0.000945	0.0159	CcSEcCtD
Pyrimethamine—Vomiting—Mitomycin—urinary bladder cancer	0.000914	0.0154	CcSEcCtD
Pyrimethamine—Haematuria—Gemcitabine—urinary bladder cancer	0.000909	0.0153	CcSEcCtD
Pyrimethamine—CYP2D6—renal system—urinary bladder cancer	0.000905	0.0275	CbGeAlD
Pyrimethamine—Pancytopenia—Etoposide—urinary bladder cancer	0.000867	0.0146	CcSEcCtD
Pyrimethamine—Erythema multiforme—Gemcitabine—urinary bladder cancer	0.000809	0.0136	CcSEcCtD
Pyrimethamine—Stevens-Johnson syndrome—Etoposide—urinary bladder cancer	0.000807	0.0136	CcSEcCtD
Pyrimethamine—Leukopenia—Thiotepa—urinary bladder cancer	0.000793	0.0133	CcSEcCtD
Pyrimethamine—CYP2D6—female reproductive system—urinary bladder cancer	0.000725	0.022	CbGeAlD
Pyrimethamine—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.000708	0.0119	CcSEcCtD
Pyrimethamine—Erythema multiforme—Etoposide—urinary bladder cancer	0.000691	0.0116	CcSEcCtD
Pyrimethamine—Anorexia—Thiotepa—urinary bladder cancer	0.000689	0.0116	CcSEcCtD
Pyrimethamine—Leukopenia—Gemcitabine—urinary bladder cancer	0.000667	0.0112	CcSEcCtD
Pyrimethamine—Leukopenia—Fluorouracil—urinary bladder cancer	0.000656	0.011	CcSEcCtD
Pyrimethamine—Decreased appetite—Thiotepa—urinary bladder cancer	0.000628	0.0106	CcSEcCtD
Pyrimethamine—Leukopenia—Cisplatin—urinary bladder cancer	0.000622	0.0105	CcSEcCtD
Pyrimethamine—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.000608	0.0102	CcSEcCtD
Pyrimethamine—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.000598	0.0101	CcSEcCtD
Pyrimethamine—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.000595	0.01	CcSEcCtD
Pyrimethamine—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.000585	0.00984	CcSEcCtD
Pyrimethamine—Anorexia—Gemcitabine—urinary bladder cancer	0.00058	0.00975	CcSEcCtD
Pyrimethamine—CYP2C8—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00057	0.00281	CbGpPWpGaD
Pyrimethamine—Anorexia—Fluorouracil—urinary bladder cancer	0.00057	0.00958	CcSEcCtD
Pyrimethamine—Toxic epidermal necrolysis—Methotrexate—urinary bladder cancer	0.00057	0.00958	CcSEcCtD
Pyrimethamine—Leukopenia—Etoposide—urinary bladder cancer	0.000569	0.00958	CcSEcCtD
Pyrimethamine—DHFR—Folate Metabolism—IL2—urinary bladder cancer	0.000569	0.0028	CbGpPWpGaD
Pyrimethamine—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.000567	0.00953	CcSEcCtD
Pyrimethamine—DHFR—Cell Cycle—ESPL1—urinary bladder cancer	0.000564	0.00278	CbGpPWpGaD
Pyrimethamine—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000555	0.00933	CcSEcCtD
Pyrimethamine—CYP2C9—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000554	0.00272	CbGpPWpGaD
Pyrimethamine—Anorexia—Cisplatin—urinary bladder cancer	0.00054	0.00908	CcSEcCtD
Pyrimethamine—Toxic epidermal necrolysis—Epirubicin—urinary bladder cancer	0.000533	0.00897	CcSEcCtD
Pyrimethamine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000533	0.00895	CcSEcCtD
Pyrimethamine—CYP2C8—Biological oxidations—UGT2B7—urinary bladder cancer	0.000529	0.0026	CbGpPWpGaD
Pyrimethamine—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000529	0.00889	CcSEcCtD
Pyrimethamine—CYP2C8—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000522	0.00257	CbGpPWpGaD
Pyrimethamine—Decreased appetite—Fluorouracil—urinary bladder cancer	0.00052	0.00874	CcSEcCtD
Pyrimethamine—Pancytopenia—Methotrexate—urinary bladder cancer	0.000519	0.00873	CcSEcCtD
Pyrimethamine—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000519	0.00873	CcSEcCtD
Pyrimethamine—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000508	0.00855	CcSEcCtD
Pyrimethamine—CYP2D6—Biological oxidations—GSTZ1—urinary bladder cancer	0.000501	0.00246	CbGpPWpGaD
Pyrimethamine—DHFR—G1/S Transition—RB1—urinary bladder cancer	0.0005	0.00246	CbGpPWpGaD
Pyrimethamine—CYP2C9—Biological oxidations—GSTZ1—urinary bladder cancer	0.000496	0.00244	CbGpPWpGaD
Pyrimethamine—DHFR—E2F transcription factor network—CDKN1A—urinary bladder cancer	0.000495	0.00244	CbGpPWpGaD
Pyrimethamine—Anorexia—Etoposide—urinary bladder cancer	0.000495	0.00832	CcSEcCtD
Pyrimethamine—CYP2D6—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000494	0.00243	CbGpPWpGaD
Pyrimethamine—Toxic epidermal necrolysis—Doxorubicin—urinary bladder cancer	0.000493	0.0083	CcSEcCtD
Pyrimethamine—Decreased appetite—Cisplatin—urinary bladder cancer	0.000493	0.00828	CcSEcCtD
Pyrimethamine—DHFR—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—urinary bladder cancer	0.000492	0.00242	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00049	0.00241	CbGpPWpGaD
Pyrimethamine—Pancytopenia—Epirubicin—urinary bladder cancer	0.000486	0.00817	CcSEcCtD
Pyrimethamine—DHFR—Mitotic G1-G1/S phases—CDK4—urinary bladder cancer	0.000485	0.00238	CbGpPWpGaD
Pyrimethamine—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000483	0.00813	CcSEcCtD
Pyrimethamine—DHFR—Cell Cycle, Mitotic—LIG1—urinary bladder cancer	0.000478	0.00235	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle, Mitotic—STAG2—urinary bladder cancer	0.000478	0.00235	CbGpPWpGaD
Pyrimethamine—CYP2C8—Biological oxidations—CYP4B1—urinary bladder cancer	0.000476	0.00234	CbGpPWpGaD
Pyrimethamine—CYP2D6—Biological oxidations—GSTO2—urinary bladder cancer	0.000475	0.00233	CbGpPWpGaD
Pyrimethamine—CYP2D6—Biological oxidations—NAT1—urinary bladder cancer	0.000475	0.00233	CbGpPWpGaD
Pyrimethamine—DHFR—E2F transcription factor network—EP300—urinary bladder cancer	0.000471	0.00232	CbGpPWpGaD
Pyrimethamine—CYP2C9—Biological oxidations—GSTO2—urinary bladder cancer	0.000471	0.00231	CbGpPWpGaD
Pyrimethamine—CYP2C9—Biological oxidations—NAT1—urinary bladder cancer	0.000471	0.00231	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00047	0.00231	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000468	0.0023	CbGpPWpGaD
Pyrimethamine—Haematuria—Methotrexate—urinary bladder cancer	0.000465	0.00782	CcSEcCtD
Pyrimethamine—CYP2C9—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000464	0.00228	CbGpPWpGaD
Pyrimethamine—Vomiting—Thiotepa—urinary bladder cancer	0.00046	0.00773	CcSEcCtD
Pyrimethamine—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000452	0.00761	CcSEcCtD
Pyrimethamine—Decreased appetite—Etoposide—urinary bladder cancer	0.000451	0.00759	CcSEcCtD
Pyrimethamine—Pancytopenia—Doxorubicin—urinary bladder cancer	0.00045	0.00756	CcSEcCtD
Pyrimethamine—DHFR—Retinoblastoma (RB) in Cancer—CCND1—urinary bladder cancer	0.000445	0.00219	CbGpPWpGaD
Pyrimethamine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00044	0.00741	CcSEcCtD
Pyrimethamine—Haematuria—Epirubicin—urinary bladder cancer	0.000435	0.00732	CcSEcCtD
Pyrimethamine—CYP2D6—Biological oxidations—UGT2B7—urinary bladder cancer	0.000434	0.00214	CbGpPWpGaD
Pyrimethamine—CYP2C9—Biological oxidations—UGT2B7—urinary bladder cancer	0.00043	0.00212	CbGpPWpGaD
Pyrimethamine—DHFR—Retinoblastoma (RB) in Cancer—CDKN1A—urinary bladder cancer	0.00043	0.00212	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000428	0.00211	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—STAG2—urinary bladder cancer	0.000428	0.0021	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—LIG1—urinary bladder cancer	0.000428	0.0021	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000424	0.00209	CbGpPWpGaD
Pyrimethamine—DHFR—Mitotic G1-G1/S phases—RB1—urinary bladder cancer	0.000421	0.00207	CbGpPWpGaD
Pyrimethamine—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000419	0.00704	CcSEcCtD
Pyrimethamine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000418	0.00702	CcSEcCtD
Pyrimethamine—DHFR—Folate Metabolism—TNF—urinary bladder cancer	0.000415	0.00204	CbGpPWpGaD
Pyrimethamine—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000414	0.00696	CcSEcCtD
Pyrimethamine—DHFR—E2F transcription factor network—MYC—urinary bladder cancer	0.000411	0.00202	CbGpPWpGaD
Pyrimethamine—CYP2C8—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000403	0.00198	CbGpPWpGaD
Pyrimethamine—Haematuria—Doxorubicin—urinary bladder cancer	0.000403	0.00677	CcSEcCtD
Pyrimethamine—DHFR—Cell Cycle, Mitotic—RRM2—urinary bladder cancer	0.000394	0.00194	CbGpPWpGaD
Pyrimethamine—CYP2D6—Biological oxidations—CYP4B1—urinary bladder cancer	0.000391	0.00192	CbGpPWpGaD
Pyrimethamine—CYP2C9—Biological oxidations—CYP4B1—urinary bladder cancer	0.000387	0.00191	CbGpPWpGaD
Pyrimethamine—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000387	0.00651	CcSEcCtD
Pyrimethamine—Vomiting—Gemcitabine—urinary bladder cancer	0.000387	0.0065	CcSEcCtD
Pyrimethamine—CYP2D6—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000386	0.0019	CbGpPWpGaD
Pyrimethamine—Hypersensitivity—Etoposide—urinary bladder cancer	0.000383	0.00643	CcSEcCtD
Pyrimethamine—CYP2C9—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000382	0.00188	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—GSTO2—urinary bladder cancer	0.000382	0.00188	CbGpPWpGaD
Pyrimethamine—Vomiting—Fluorouracil—urinary bladder cancer	0.00038	0.00639	CcSEcCtD
Pyrimethamine—DHFR—Mitotic G1-G1/S phases—CDKN2A—urinary bladder cancer	0.000371	0.00182	CbGpPWpGaD
Pyrimethamine—DHFR—Folate Metabolism—TP53—urinary bladder cancer	0.000366	0.0018	CbGpPWpGaD
Pyrimethamine—Vomiting—Cisplatin—urinary bladder cancer	0.00036	0.00606	CcSEcCtD
Pyrimethamine—DHFR—G1/S Transition—CDKN1A—urinary bladder cancer	0.000359	0.00177	CbGpPWpGaD
Pyrimethamine—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000358	0.00603	CcSEcCtD
Pyrimethamine—DHFR—Retinoblastoma (RB) in Cancer—MYC—urinary bladder cancer	0.000357	0.00176	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—RRM2—urinary bladder cancer	0.000352	0.00173	CbGpPWpGaD
Pyrimethamine—Leukopenia—Methotrexate—urinary bladder cancer	0.000341	0.00574	CcSEcCtD
Pyrimethamine—DHFR—Metabolism—GSTZ1—urinary bladder cancer	0.000337	0.00166	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle, Mitotic—SMC1A—urinary bladder cancer	0.000335	0.00165	CbGpPWpGaD
Pyrimethamine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000334	0.00164	CbGpPWpGaD
Pyrimethamine—Vomiting—Etoposide—urinary bladder cancer	0.00033	0.00555	CcSEcCtD
Pyrimethamine—CYP2C9—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000328	0.00161	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—GSTO2—urinary bladder cancer	0.00032	0.00157	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—NAT1—urinary bladder cancer	0.00032	0.00157	CbGpPWpGaD
Pyrimethamine—Leukopenia—Epirubicin—urinary bladder cancer	0.000319	0.00537	CcSEcCtD
Pyrimethamine—CYP2C8—Biological oxidations—NAT2—urinary bladder cancer	0.000317	0.00156	CbGpPWpGaD
Pyrimethamine—DHFR—Mitotic G1-G1/S phases—CCND1—urinary bladder cancer	0.000313	0.00154	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000312	0.00154	CbGpPWpGaD
Pyrimethamine—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000311	0.00523	CcSEcCtD
Pyrimethamine—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000304	0.00512	CcSEcCtD
Pyrimethamine—DHFR—Mitotic G1-G1/S phases—CDKN1A—urinary bladder cancer	0.000303	0.00149	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—SMC1A—urinary bladder cancer	0.000299	0.00147	CbGpPWpGaD
Pyrimethamine—DHFR—G1/S Transition—MYC—urinary bladder cancer	0.000298	0.00147	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—SLC19A1—urinary bladder cancer	0.000297	0.00146	CbGpPWpGaD
Pyrimethamine—Anorexia—Methotrexate—urinary bladder cancer	0.000296	0.00498	CcSEcCtD
Pyrimethamine—Leukopenia—Doxorubicin—urinary bladder cancer	0.000295	0.00497	CcSEcCtD
Pyrimethamine—DHFR—Retinoblastoma (RB) in Cancer—TP53—urinary bladder cancer	0.000293	0.00144	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—UGT2B7—urinary bladder cancer	0.000293	0.00144	CbGpPWpGaD
Pyrimethamine—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000291	0.00489	CcSEcCtD
Pyrimethamine—DHFR—Disease—PRSS3—urinary bladder cancer	0.00029	0.00142	CbGpPWpGaD
Pyrimethamine—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000285	0.00479	CcSEcCtD
Pyrimethamine—Anorexia—Epirubicin—urinary bladder cancer	0.000277	0.00466	CcSEcCtD
Pyrimethamine—DHFR—Disease—HDAC4—urinary bladder cancer	0.000276	0.00136	CbGpPWpGaD
Pyrimethamine—Decreased appetite—Methotrexate—urinary bladder cancer	0.00027	0.00455	CcSEcCtD
Pyrimethamine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000269	0.00453	CcSEcCtD
Pyrimethamine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000264	0.00443	CcSEcCtD
Pyrimethamine—DHFR—Metabolism—CYP4B1—urinary bladder cancer	0.000263	0.0013	CbGpPWpGaD
Pyrimethamine—CYP2D6—Biological oxidations—NAT2—urinary bladder cancer	0.00026	0.00128	CbGpPWpGaD
Pyrimethamine—CYP2C9—Biological oxidations—NAT2—urinary bladder cancer	0.000258	0.00127	CbGpPWpGaD
Pyrimethamine—Anorexia—Doxorubicin—urinary bladder cancer	0.000257	0.00432	CcSEcCtD
Pyrimethamine—CYP2D6—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000257	0.00126	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000254	0.00125	CbGpPWpGaD
Pyrimethamine—CYP2C8—Biological oxidations—HPGDS—urinary bladder cancer	0.000253	0.00125	CbGpPWpGaD
Pyrimethamine—Decreased appetite—Epirubicin—urinary bladder cancer	0.000253	0.00425	CcSEcCtD
Pyrimethamine—DHFR—Mitotic G1-G1/S phases—MYC—urinary bladder cancer	0.000251	0.00124	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—SLC19A1—urinary bladder cancer	0.000249	0.00122	CbGpPWpGaD
Pyrimethamine—CYP2C8—Biological oxidations—GSTT1—urinary bladder cancer	0.000246	0.00121	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—PRSS3—urinary bladder cancer	0.000242	0.00119	CbGpPWpGaD
Pyrimethamine—CYP2C8—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000237	0.00117	CbGpPWpGaD
Pyrimethamine—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000234	0.00394	CcSEcCtD
Pyrimethamine—DHFR—Cell Cycle, Mitotic—CCNE1—urinary bladder cancer	0.000232	0.00114	CbGpPWpGaD
Pyrimethamine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000229	0.00385	CcSEcCtD
Pyrimethamine—DHFR—Cell Cycle, Mitotic—TYMS—urinary bladder cancer	0.000228	0.00112	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—LIG1—urinary bladder cancer	0.000219	0.00108	CbGpPWpGaD
Pyrimethamine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000214	0.00361	CcSEcCtD
Pyrimethamine—CYP2D6—Biological oxidations—HPGDS—urinary bladder cancer	0.000208	0.00102	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—CCNE1—urinary bladder cancer	0.000208	0.00102	CbGpPWpGaD
Pyrimethamine—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	0.000206	0.00101	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—TYMS—urinary bladder cancer	0.000204	0.001	CbGpPWpGaD
Pyrimethamine—CYP2D6—Biological oxidations—GSTT1—urinary bladder cancer	0.000202	0.000992	CbGpPWpGaD
Pyrimethamine—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	0.0002	0.000983	CbGpPWpGaD
Pyrimethamine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000198	0.00334	CcSEcCtD
Pyrimethamine—Vomiting—Methotrexate—urinary bladder cancer	0.000198	0.00332	CcSEcCtD
Pyrimethamine—DHFR—Metabolism—TYMP—urinary bladder cancer	0.000194	0.000954	CbGpPWpGaD
Pyrimethamine—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000193	0.000949	CbGpPWpGaD
Pyrimethamine—Vomiting—Epirubicin—urinary bladder cancer	0.000185	0.00311	CcSEcCtD
Pyrimethamine—CYP2C8—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000183	0.000899	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle, Mitotic—CDK4—urinary bladder cancer	0.000178	0.000875	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—TERT—urinary bladder cancer	0.000178	0.000874	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—NAT2—urinary bladder cancer	0.000175	0.000862	CbGpPWpGaD
Pyrimethamine—Vomiting—Doxorubicin—urinary bladder cancer	0.000171	0.00288	CcSEcCtD
Pyrimethamine—CYP2C8—Biological oxidations—GSTP1—urinary bladder cancer	0.00017	0.000838	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000168	0.000826	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—ENO2—urinary bladder cancer	0.000167	0.000823	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—ATM—urinary bladder cancer	0.00016	0.000785	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—CDK4—urinary bladder cancer	0.000159	0.000782	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—RBX1—urinary bladder cancer	0.000159	0.00078	CbGpPWpGaD
Pyrimethamine—CYP2C8—Biological oxidations—GSTM1—urinary bladder cancer	0.000156	0.00077	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle, Mitotic—RB1—urinary bladder cancer	0.000155	0.00076	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000154	0.000759	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—RRM2—urinary bladder cancer	0.000151	0.000744	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000149	0.000732	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—JAG1—urinary bladder cancer	0.000142	0.000698	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—HPGDS—urinary bladder cancer	0.00014	0.000689	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—ENO2—urinary bladder cancer	0.00014	0.000689	CbGpPWpGaD
Pyrimethamine—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	0.00014	0.000688	CbGpPWpGaD
Pyrimethamine—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	0.000139	0.000682	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—RB1—urinary bladder cancer	0.000138	0.00068	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000138	0.000678	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000137	0.000672	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—GSTT1—urinary bladder cancer	0.000136	0.000669	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle, Mitotic—CDKN2A—urinary bladder cancer	0.000136	0.000668	CbGpPWpGaD
Pyrimethamine—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	0.000128	0.000632	CbGpPWpGaD
Pyrimethamine—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	0.000127	0.000626	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000127	0.000623	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000126	0.000618	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—CDKN2A—urinary bladder cancer	0.000122	0.000598	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	0.000115	0.000565	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—NQO1—urinary bladder cancer	0.000113	0.000556	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	0.000111	0.000546	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle, Mitotic—EP300—urinary bladder cancer	0.000106	0.00052	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—GSTZ1—urinary bladder cancer	0.000104	0.000513	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—NCOR1—urinary bladder cancer	0.000103	0.000509	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—CCND1—urinary bladder cancer	0.000103	0.000505	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—CDKN1A—urinary bladder cancer	9.93e-05	0.000488	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—GSTO2—urinary bladder cancer	9.89e-05	0.000486	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—NAT1—urinary bladder cancer	9.89e-05	0.000486	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	9.72e-05	0.000478	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—ERCC2—urinary bladder cancer	9.72e-05	0.000478	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—EP300—urinary bladder cancer	9.45e-05	0.000465	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—GSTP1—urinary bladder cancer	9.42e-05	0.000463	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle, Mitotic—MYC—urinary bladder cancer	9.21e-05	0.000453	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—MTHFR—urinary bladder cancer	9.14e-05	0.000449	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—TERT—urinary bladder cancer	9.11e-05	0.000448	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—UGT2B7—urinary bladder cancer	9.04e-05	0.000445	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—TYMS—urinary bladder cancer	8.76e-05	0.000431	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—GSTM1—urinary bladder cancer	8.66e-05	0.000426	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—NCOR1—urinary bladder cancer	8.66e-05	0.000426	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	8.56e-05	0.000421	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	8.49e-05	0.000418	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—FGFR3—urinary bladder cancer	8.36e-05	0.000411	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—GPX1—urinary bladder cancer	8.29e-05	0.000408	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—MYC—urinary bladder cancer	8.23e-05	0.000405	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—CYP4B1—urinary bladder cancer	8.14e-05	0.000401	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—ERCC2—urinary bladder cancer	8.14e-05	0.0004	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	8.12e-05	0.000399	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—NAT1—urinary bladder cancer	8.12e-05	0.000399	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	8.05e-05	0.000396	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—NAT1—urinary bladder cancer	8.05e-05	0.000396	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	7.91e-05	0.000389	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—SLC19A1—urinary bladder cancer	7.69e-05	0.000378	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—MTHFR—urinary bladder cancer	7.65e-05	0.000376	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—PRSS3—urinary bladder cancer	7.49e-05	0.000369	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	7.42e-05	0.000365	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	7.36e-05	0.000362	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—CREBBP—urinary bladder cancer	7.12e-05	0.00035	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—TP53—urinary bladder cancer	6.76e-05	0.000333	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	6.68e-05	0.000329	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	6.63e-05	0.000326	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—RHOA—urinary bladder cancer	6.44e-05	0.000317	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	6.31e-05	0.000311	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	6.26e-05	0.000308	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—PPARG—urinary bladder cancer	6.2e-05	0.000305	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	6.15e-05	0.000303	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	6.1e-05	0.0003	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	6.01e-05	0.000296	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—TYMP—urinary bladder cancer	5.99e-05	0.000295	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—CREBBP—urinary bladder cancer	5.96e-05	0.000293	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—ERBB2—urinary bladder cancer	5.96e-05	0.000293	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—PTGS2—urinary bladder cancer	5.83e-05	0.000287	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	5.75e-05	0.000283	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—NAT2—urinary bladder cancer	5.42e-05	0.000266	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—CDKN1A—urinary bladder cancer	5.09e-05	0.000251	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—PTEN—urinary bladder cancer	5.08e-05	0.00025	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—TYMP—urinary bladder cancer	4.92e-05	0.000242	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.89e-05	0.000241	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—PTGS2—urinary bladder cancer	4.88e-05	0.00024	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—TYMP—urinary bladder cancer	4.88e-05	0.00024	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—EP300—urinary bladder cancer	4.85e-05	0.000238	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—SRC—urinary bladder cancer	4.71e-05	0.000232	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.68e-05	0.00023	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—RRM2—urinary bladder cancer	4.68e-05	0.00023	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—NAT2—urinary bladder cancer	4.45e-05	0.000219	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—NAT2—urinary bladder cancer	4.41e-05	0.000217	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—ENO2—urinary bladder cancer	4.33e-05	0.000213	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—HPGDS—urinary bladder cancer	4.33e-05	0.000213	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.31e-05	0.000212	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—PTEN—urinary bladder cancer	4.26e-05	0.000209	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—MYC—urinary bladder cancer	4.22e-05	0.000208	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—GSTT1—urinary bladder cancer	4.2e-05	0.000207	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	4.14e-05	0.000203	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—EGFR—urinary bladder cancer	4.13e-05	0.000203	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—EP300—urinary bladder cancer	4.06e-05	0.0002	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—KRAS—urinary bladder cancer	3.9e-05	0.000192	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—RRM2—urinary bladder cancer	3.84e-05	0.000189	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—RRM2—urinary bladder cancer	3.81e-05	0.000187	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	3.56e-05	0.000175	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—ENO2—urinary bladder cancer	3.56e-05	0.000175	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—ENO2—urinary bladder cancer	3.52e-05	0.000173	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	3.52e-05	0.000173	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.5e-05	0.000172	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—NQO1—urinary bladder cancer	3.49e-05	0.000172	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	3.45e-05	0.00017	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	3.42e-05	0.000168	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.39e-05	0.000167	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.37e-05	0.000166	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—HRAS—urinary bladder cancer	3.32e-05	0.000163	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.95e-05	0.000145	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—GSTP1—urinary bladder cancer	2.91e-05	0.000143	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—NQO1—urinary bladder cancer	2.87e-05	0.000141	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—NQO1—urinary bladder cancer	2.84e-05	0.00014	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.82e-05	0.000139	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.76e-05	0.000136	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—TYMS—urinary bladder cancer	2.71e-05	0.000133	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—GSTM1—urinary bladder cancer	2.68e-05	0.000132	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—NCOR1—urinary bladder cancer	2.68e-05	0.000132	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—GPX1—urinary bladder cancer	2.56e-05	0.000126	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—ERCC2—urinary bladder cancer	2.52e-05	0.000124	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.4e-05	0.000118	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	2.39e-05	0.000118	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	2.37e-05	0.000117	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—MTHFR—urinary bladder cancer	2.36e-05	0.000116	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.29e-05	0.000113	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—TYMS—urinary bladder cancer	2.22e-05	0.000109	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—TYMS—urinary bladder cancer	2.2e-05	0.000108	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	2.2e-05	0.000108	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	2.2e-05	0.000108	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	2.18e-05	0.000107	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	2.18e-05	0.000107	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—GPX1—urinary bladder cancer	2.1e-05	0.000103	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—GPX1—urinary bladder cancer	2.09e-05	0.000103	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	2.07e-05	0.000102	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	2.05e-05	0.000101	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	1.94e-05	9.55e-05	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	1.92e-05	9.47e-05	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—PPARG—urinary bladder cancer	1.92e-05	9.43e-05	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—CREBBP—urinary bladder cancer	1.84e-05	9.06e-05	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	1.57e-05	7.74e-05	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—PPARG—urinary bladder cancer	1.56e-05	7.68e-05	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	1.51e-05	7.44e-05	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—PTGS2—urinary bladder cancer	1.51e-05	7.42e-05	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	1.5e-05	7.37e-05	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—PTEN—urinary bladder cancer	1.32e-05	6.47e-05	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—EP300—urinary bladder cancer	1.25e-05	6.17e-05	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.24e-05	6.09e-05	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	1.23e-05	6.04e-05	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.08e-05	5.31e-05	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—PTEN—urinary bladder cancer	1.07e-05	5.27e-05	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—EP300—urinary bladder cancer	1.03e-05	5.07e-05	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—EP300—urinary bladder cancer	1.02e-05	5.02e-05	CbGpPWpGaD
